DYN Dyne Therapeutics, Inc.

NEUTRAL Impact: 2/10 144
Horizon immediate Filed May 4, 2026 Processed 19d 5h ago SEC 0001628280-26-029910
Form 144 — notice of proposed sale of securities
Latest settled — T+5d ⚠ clustered
DYN ▲ +5.15% at T+5d
NEUTRAL call ✓ call won +5.15% · α vs SPY +3.17% · entry $17.47 → $18.37
Next anchor: T+20d in 9d
Last close $17.37 (close May 22) · -0.57% from $17.47 entry
Entry anchored
May 4, 2026
via day open
T+1d
+7.84%
call +7.84% · α +6.46%
$18.84
settled 19d ago
T+5d
+5.15%
call +5.15% · α +3.17%
$18.37
settled 13d ago
T+20d
call — · α —
in 9d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Atlas Venture Opportunity Fund I, L.P., a major venture investor, filed a Form 144 indicating intent to sell 2,466 shares of Dyne Therapeutics, with an estimated value of approximately $42,884. The proposed sale is tiny relative to Dyne's $2.9B market cap and appears to be routine portfolio rebalancing. However, the filing comes amid a cluster of 9 insider sales totaling $8.6M over the past 30 days, which merits attention.

Actionable Insight

This filing alone is not material. However, the broader pattern of elevated insider selling (9 transactions, $8.6M over 30 days) warrants monitoring for potential negative sentiment. Watch for any material adverse news or guidance changes in upcoming filings.

Key Facts

  • Filing by Atlas Venture Opportunity Fund I, L.P., a VC fund, not an officer/director.
  • Proposed sale of 2,466 shares of Dyna Therapeutics common stock.
  • Estimated market value of ~$42,884 (based on current price).
  • Filing date: 2026-05-04.
  • Proposed sale represents ~0.0015% of market cap (negligible).
  • Recent insider selling cluster: 9 sales totaling $8.6M in the last 30 days.

Financial Impact

Negligible; proposed sale value of ~$42,884 is minimal relative to ~$2.9B market cap.

dilution

Risk Factors

  • Insider selling cluster may indicate negative outlook, but this specific filing is too small to be a signal.
  • Venture fund sale could be routine liquidity event, not necessarily informed selling.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (20 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-029910
Document: 0001628280-26-029910-index.html0001628280-26-029910
Document: 0001628280-26-029910.txt0001628280-26-029910
25 reports for DYN
Performance horizon
100% Hit rate 6 of 6 directional calls best @ T+20▲ +13.90%Apr 20, 2026
Filters
Rows
Reports for DYN — sortable, filterable
Type Now
May 20, 2026
3d ago
Press Release
NEUTRAL ★ 2/10
$17.60 awaiting T+5awaiting T+5$17.37 (−1.31%)
May 20, 2026
3d ago
Press Release
BULLISH ★ 7/10
awaiting T+5
May 13, 2026
10d ago
144
NEUTRAL ★ 2/10
awaiting T+5
May 13, 2026
10d ago
144
NEUTRAL ★ 2/10
awaiting T+5
May 11, 2026
12d ago
8-K
NEUTRAL ★ 5/10
$18.46 $16.54▼ −10.40%▼ −10.32%$17.37 (−5.90%)
May 6, 2026
17d ago
144
NEUTRAL ★ 2/10
$17.54 $18.44▲ +5.13%▲ +3.63%$17.37 (−0.97%)
May 6, 2026
17d ago
144
NEUTRAL ★ 2/10
$17.54 $18.44▲ +5.13%▲ +3.63%$17.37 (−0.97%)
May 4, 2026
19d ago
144
NEUTRAL ★ 2/10
$17.47 $18.37▲ +5.15%▲ +3.17%$17.37 (−0.57%)
May 4, 2026
19d ago
144
NEUTRAL ★ 2/10
$17.47 $18.37▲ +5.15%▲ +3.17%$17.37 (−0.57%)
May 4, 2026
19d ago
144
NEUTRAL ★ 2/10
$17.47 $18.37▲ +5.15%▲ +3.17%$17.37 (−0.57%)
Showing 10 of 25

US Market Status

Market Closed — Opens Tue (35h 14m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access